Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical study protocol for a low-interventional study in intermediate age-related macular degeneration developing novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention-MACUSTAR.
Terheyden JH, Holz FG, Schmitz-Valckenberg S, Lüning A, Schmid M, Rubin GS, Dunbar H, Tufail A, Crabb DP, Binns A, Sánchez CI, Hoyng C, Margaron P, Zakaria N, Durbin M, Luhmann U, Zamiri P, Cunha-Vaz J, Martinho C, Leal S, Finger RP; MACUSTAR consortium. Terheyden JH, et al. Trials. 2020 Jul 18;21(1):659. doi: 10.1186/s13063-020-04595-6. Trials. 2020. PMID: 32682441 Free PMC article.
Challenges, facilitators and barriers to screening study participants in early disease stages-experience from the MACUSTAR study.
Terheyden JH, Behning C, Lüning A, Wintergerst L, Basile PG, Tavares D, Melício BA, Leal S, Weissgerber G, Luhmann UFO, Crabb DP, Tufail A, Hoyng C, Berger M, Schmid M, Silva R, Martinho CV, Cunha-Vaz J, Holz FG, Finger RP; MACUSTAR consortium. Terheyden JH, et al. Among authors: behning c. BMC Med Res Methodol. 2021 Mar 17;21(1):54. doi: 10.1186/s12874-021-01243-8. BMC Med Res Methodol. 2021. PMID: 33731014 Free PMC article.
Disease-specific assessment of Vision Impairment in Low Luminance in age-related macular degeneration - a MACUSTAR study report.
Terheyden JH, Pondorfer SG, Behning C, Berger M, Carlton J, Rowen D, Bouchet C, Poor S, Luhmann UFO, Leal S, Holz FG, Butt T, Brazier JE, Finger RP; MACUSTAR consortium. Terheyden JH, et al. Among authors: behning c. Br J Ophthalmol. 2023 Aug;107(8):1144-1150. doi: 10.1136/bjophthalmol-2021-320848. Epub 2022 Mar 30. Br J Ophthalmol. 2023. PMID: 35354561 Free PMC article. Clinical Trial.
Characteristics and Spatial Distribution of Structural Features in Age-Related Macular Degeneration: A MACUSTAR Study Report.
Saßmannshausen M, Behning C, Weinz J, Goerdt L, Terheyden JH, Chang P, Schmid M, Poor SH, Zakaria N, Finger RP, Holz FG, Pfau M, Schmitz-Valckenberg S, Thiele S; MACUSTAR Consortium Members. Saßmannshausen M, et al. Among authors: behning c. Ophthalmol Retina. 2023 May;7(5):420-430. doi: 10.1016/j.oret.2022.12.007. Epub 2022 Dec 20. Ophthalmol Retina. 2023. PMID: 36563964 Free article.
Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
Verspohl SH, Holderried T, Behning C, Brossart P, Schäfer VS. Verspohl SH, et al. Among authors: behning c. Ther Adv Musculoskelet Dis. 2021 Apr 12;13:1759720X211006963. doi: 10.1177/1759720X211006963. eCollection 2021. Ther Adv Musculoskelet Dis. 2021. PMID: 33912248 Free PMC article.
36 results